title: Immune checkpoint inhibitors side effects and management.
abstract: The next decade in cancer therapy will be marked by the expansion of immunotherapies, namely immune checkpoint inhibitors. The increasing number and combination of checkpoint inhibitors and the variety of their mechanisms of action and indications will most likely multiply the side effects associated with these therapies and make their management more complicated and diversified. Given the growing rate of approval of different checkpoint inhibitors in different cancers in multiple settings, a review summarizing the major side effects of the new agents in use today and their management seems to be appropriate. Highlighting these adverse events and their management in a single review might help the daily practice of the physicians and consequently contribute the patient's safety and quality of life.
authors.affiliation: Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Bruxelles, Belgium.
authors.forename: Hampig Raphael
authors.initials: HR
authors.lastname: Kourie
authors.affiliation: Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Bruxelles, Belgium.
authors.forename: Jean
authors.initials: J
authors.lastname: Klastersky
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D061025:Costimulatory and Inhibitory T-Cell Receptors / Q000276:immunology*; D019468:Disease Management; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents; D061025:Costimulatory and Inhibitory T-Cell Receptors
keywords: checkpoint inhibitors; immunotherapy; side effects